Sirolimus Eluting Coronary Stent System
Yilson Development Co.,Ltd [China] 
Descriptions:
Biodegradable Polymer Coating Proven Safety and Efficacy Profile
Biodegradable Polymer Coating Proven Safety and Efficacy Profile
*This DES uses a biodegradable polymer coating on the stainless steel stent platform. The proprietary, top-quality coating process allows the integrity of coated polymer after excessive stent expansion and a systemic elution of sirolimus in a well -controlled fashion after the stent implantation. The safety and efficacy of the product is well documented from a related randomized trial in Europe in CTO patients showing low re-stenosis rate and very promising late loss data.
|
Specifications:
|
|
|
Stent Plaform
|
316L Stainless Steel
|
|
Coating Material
|
PLGA (Biodegradable)
|
|
Coating Thickness
|
4.0±1.0μm
|
|
Drug
|
Sirolimus (Rapamycine)
|
|
Drug Content
|
170μg/cm2±20μg/cm2 (12mm,18mm)
|
|
150μg/cm2±20μg/cm2 (23mm,28mm,33mm)
|
|
|
Degradation Time
|
>2Months
|
|
Clinical Results in 90 Patients with CTO:
|
||
|
Control Group
|
Rapa
|
BMS
|
|
6 Month MACE
|
0%
|
0%
|
|
6 Month TVR
|
11%
|
55%
|
|
6 Month TLR
|
4%
|
19%
|
|
6 Month In-Stent Restenosis
|
16%
|
61%
|
|
6 Month In-Stent Late loss
|
0.41mm
|
1.46mm
|
|
|||||||||
|
Length
|
9
|
12
|
16
|
18
|
20
|
23
|
28
|
33
|
|
|
Diameter
|
|||||||||
|
2.50
|
√
|
√
|
√
|
√
|
|
√
|
|
|
|
|
2.75
|
√
|
√
|
√
|
√
|
√
|
√
|
|
|
|
|
3.00
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
|
|
3.50
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
|
|
4.00
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
|
